BPC-157 vs GHK

Recovery

Cosmetic

Under 2026 FDA Review

Research Only

Preclinical studies suggest BPC-157 promotes angiogenesis and granulation tissue formation, with reported upregulation of VEGFR2 signaling and activation of the FAK-paxillin pathway in tendon fibroblasts. It has also been reported to modulate the nitric oxide system and interact with dopaminergic and serotonergic pathways along the gut-brain axis. A precise receptor target has not been established.

GHK is a high-affinity ligand for copper(II), forming the GHK-Cu complex that mediates most of its documented biology. Via the copper-bound form, GHK is proposed to modulate expression of a large number of human genes (microarray and Broad Institute Connectivity Map analyses from Pickart's group), including pathways related to extracellular matrix remodeling, antioxidant response element induction, angiogenesis, and DNA repair. Reported in vitro and preclinical effects include stimulation of fibroblast collagen and glycosaminoglycan synthesis and acceleration of wound healing. The bare (non-copper) peptide is typically weaker than GHK-Cu in these assays and is generally assumed to acquire copper in serum-containing environments.

250–500 mcg (community-reported, not clinically validated)

50–200 ppm topical (~0.005–0.02%)

SubQ or Oral

Topical